<DOC>
	<DOCNO>NCT01787539</DOCNO>
	<brief_summary>Taking account substantial doubt concern potential benefit postoperative part perioperative chemotherapy regimen design study assess value approach gastric cancer . To improve compliance protocol regimen aggressive combine therapy replace test MAGIC trial ECF regimen effective well tolerable EOX chemotherapy regimen . The value postoperative three-cycle EOX regimen test patient locoregionally advanced gastric cancer positive pathological response preoperative three-cycle EOX chemotherapy regimen . The patient randomize postoperative chemotherapy follow-up arm .</brief_summary>
	<brief_title>The Role Postoperative Cycles Perioperative Chemotherapy Gastric Cancer</brief_title>
	<detailed_description>The MAGIC trial , also consider `` milestone '' study , definitely prove neoadjuvant chemotherapy improve outcome patient locally advanced gastric cancer . Resection consider curative 79 % combination therapy versus 69 % operated patient ( P = 0.02 ) , 2-year survival rate 50 41 % , 5-year-survival rate 36 23 % ( P = 0.009 ) , respectively . The substantial weak point MAGIC trial remain fact 40 % patient receive full dosage schedule postoperative chemotherapy , mainly due intolerance toxicity reason . The noninferiority relation survival capecitabine 5-FU triplet regimen treatment patient advance esophagogastric cancer demonstrate large multicenter randomize phase III , REAL-2 study , include 1002 patient . Capecitabine overcome doubt concern potential efficacy oral drug administration patient gastric carcinoma , especially relation patient undergo partial total gastrectomy . The study demonstrate noninferiority oxaliplatin versus cisplatin advance gastric cancer confirm acceptable tolerability profile third-generation platinum analogue . It anticipate use newer agent component triplet regimen would reduce toxicity thereby render alternative standard ECF combination easy handle consequence replace cisplatin component oxaliplatin , replace infusional 5-fluorouracil component oral capecitabine EOX regimen . Furthermore , achieve median overall survival time 11.2 month , EOX regimen appear active ECF ( median overall survival time , 9.9 month ) , high 1-year survival rate 47 % vs 38 % , respectively . Compared ECF regimen , EOX associate significantly low rate grade 3 4 neutropenia grade 2 alopecia , significantly high rate grade 3 4 lethargy , diarrhea , peripheral neuropathy . Based result REAL study , EOX therefore tolerable , least active ECF . This modified regimen could therefore consider new standard treatment may appropriate reference regimen future study advance gastric cancer .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>histopathologically confirm gastric cancer potentially resectable , local locoregional cancer clinical stag cT24aN03M0 . A clinical assessment location , resectability stag perform base endoscopy , barium swallow , endoscopic ultrasound , multidetector compute tomography diagnostic laparoscopy cytology wash . medically fit undergo major abdominal surgery general condition allow tolerate longlasting chemotherapy ( Karnofsky Performance Status ≥70 , ECOG 01 ) Pregnancy breast feeding . Diagnosed malignancy and/or chemotherapy administrate within last 5 year Gastric remnant cancer ; Early Gastric Cancer ; Irresectable disseminate cancer distant organ metastasis and/or peritoneal spread and/or positive cytology wash Poor performance status measure Karnofsky index &lt; 60 ECOG &lt; 1 Clinically important active systemic disease : unstable diabetes , circulatory failure NYHA III IV , unstable arterial hypertension , unstable coronary heart disease , recent heart infarct brain insult within last 6 month , severe COPD , peripheral neuropathy grade 24 ; Severe hematological abnormality : HGB &lt; 10.0 gm/dL and/or neutropenia &lt; 1500 /mm3 ; PLT &lt; 100 000 /mm3 . Severe renal dysfunction require peritoneal dialysis , hemodialysis hemofiltration oliguria &lt; 20ml/h . Severe liver dysfunction : acute chronic hepatitis , liver cirrhosis , liver failure , abnormal liver testing : ALAT ASPAT ALP &gt; 2.5 5.0 × upper limit ; total bilirubin &gt; 2 x upper limit . Concommitant infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>perioperative chemotherapy</keyword>
	<keyword>combine modality therapy</keyword>
	<keyword>gastrectomy</keyword>
</DOC>